{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:31:33Z","timestamp":1790109093851,"version":"4.0.1"},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Macroprolactinomas are rarely seen in women, and pregnancy is a risk factor for tumor growth. More studies are needed to determine appropriate management for macroprolactinoma and pregnancy. The aim of our study is to evaluate effects of treatment with dopamine agonists on macroadenoma before and during pregnancy, safety of dopamine agonists on fetus, post-pregnancy prognosis and long-term results. This is a single center retrospective study. Thirty-four pregnancies occurred in 21 patients under medical therapy. Prolactin levels, treatment results, tumor diameter changes, maternal-fetal outcomes, and disease activity were evaluated. The median tumor size at the time of diagnosis was 15 mm (10\u201328). Residual adenoma diameter was smaller in those receiving medical therapy longer than one year till the conception (p=0.047). Treatment was discontinued in 28 pregnancies after pregnancy confirmation, and 6 patients were exposed to bromocriptine throughout pregnancy. There was no symptomatic tumor growth during gestation. Among 27 live births, none of the fetuses developed neonatal malformation except for a case of Down syndrome. While early remission rate after pregnancy was 9.5%, this rate reached 33.3% at last follow-up visit. Lowered PRL levels at postpartum period (p=0.040), smaller tumor size at last follow-up visit (p=0.030), and total disappearance of tumor (p=0.026) were the contributor factors for remission. Use of dopamine agonist over one year may reduce the risk of symptomatic tumor growth during pregnancy in patients without invasive or large macroprolactinoma before pregnancy. Exposure to dopamine agonists seems generally safe for the fetus.<\/jats:p>","DOI":"10.1055\/a-1468-4608","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:09:23Z","timestamp":1619482163000},"page":"371-376","source":"Crossref","is-referenced-by-count":8,"title":["Outcomes of Patients with Macroprolactinoma Desiring Pregnancy: Follow-Up to 23 Years from a Single Center"],"prefix":"10.1055","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9220-6118","authenticated-orcid":false,"given":"Seher","family":"Tanrikulu","sequence":"additional","affiliation":[{"name":"Istanbul University, Division of Endocrinology and Metabolism, Istanbul, Turkey"},{"name":"Istanbul Haydarpa\u015fa Numune Health Training and Research Hospital, Division of Endocrinology and Metabolism, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema","family":"Yarman","sequence":"additional","affiliation":[{"name":"Istanbul University, Division of Endocrinology and Metabolism, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"M P Gillam","year":"2006","journal-title":"Endocr Rev"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"R205","DOI":"10.1530\/EJE-14-0848","article-title":"Endocrinology in pregnancy: Management of the pregnant patient with a prolactinoma","volume":"172","author":"M E Molitch","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1055\/s-0043-112861","article-title":"Pregnancy and tumor outcomes in women with prolactinoma","volume":"125","author":"B Araujo","year":"2017","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline","volume":"96","author":"S Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/a-0794-7587","article-title":"Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment?","volume":"79","author":"S Petersenn","year":"2019","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1210\/jc.2012-3039","article-title":"Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation","volume":"98","author":"R S Auriemma","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ecl.2019.05.004","article-title":"Pituitary tumors in pregnancy","volume":"48","author":"W Huang","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"E96","DOI":"10.25011\/cim.v35i2.16293","article-title":"Management of prolactinomas during pregnancy \u2013 a survey of four Canadian provinces","volume":"35","author":"M H Almalki","year":"2012","journal-title":"Clin Invest Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2265.2007.03000.x","article-title":"Pregnancy outcomes following cabergoline treatment: Extended results from a 12-year observational study","volume":"68","author":"A Colao","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12020-014-0334-7","article-title":"cabergoline, and pregnancy","volume":"47","author":"A Glezer","year":"2014","journal-title":"Endocrine"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2265.2010.03808.x","article-title":"Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women","volume":"73","author":"M Lebbe","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","article-title":"Prevalence of pituitary adenomas: A community-based, cross-sectional study in Banbury (Oxfordshire, UK)","volume":"72","author":"A Fernandez","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12370","article-title":"Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients","volume":"80","author":"M E Domingue","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/ajo.13070","article-title":"An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists","volume":"60","author":"S M O'Sullivan","year":"2020","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1210\/jc.2009-2605","article-title":"Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas","volume":"95","author":"M Ono","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11102-019-01008-z","article-title":"A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas","volume":"23","author":"B G Sant' Anna","year":"2020","journal-title":"Pituitary"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40618-017-0709-8","article-title":"How does pregnancy affect the patients with pituitary adenomas: a study on 113 pregnancies from Turkey","volume":"41","author":"Z Karaca","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11102-019-01010-5","article-title":"Prolactinomas in pregnancy: considerations before conception and during pregnancy","volume":"23","author":"A Glezer","year":"2020","journal-title":"Pituitary"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1530\/acta.0.1110452","article-title":"Women with prolactinoma\u2013effect of pregnancy and lactation on serum prolactin and on tumour growth","volume":"111","author":"U Holmgren","year":"1986","journal-title":"Acta Endocrinol (Copenh)"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"F F Casanueva","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/cen.14162","article-title":"Evolution of macroprolactinomas during pregnancy: A cohort study of 85 pregnancies","volume":"92","author":"S Barraud","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.25179\/tjem.2017-57578","article-title":"Review of Clinical Recommendations on Prolactinoma and Pregnancy","volume":"22","author":"G Y Yalin","year":"2018","journal-title":"Turk J Endocrinol Metab"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1210\/jcem-48-1-9","article-title":"A pregnancy in an acromegalic woman during bromocriptine treatment: Effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments","volume":"48","author":"M Bigazzi","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000180100","article-title":"Follow-up of children born of bromocriptine-treated mothers","volume":"22","author":"J P Raymond","year":"1985","journal-title":"Horm Res"},{"key":"ref25","first-page":"160","year":"2018"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11102-010-0243-6","article-title":"Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature","volume":"13","author":"G Stalldecker","year":"2010","journal-title":"Pituitary"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0015-0282(16)45806-1","article-title":"Bromocriptine as prophylactic therapy in prolactinoma during pregnancy","volume":"36","author":"E S Canales","year":"1981","journal-title":"Fertil Steril"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/0002-9378(83)90968-7","article-title":"Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas","volume":"146","author":"P Konopka","year":"1983","journal-title":"Am J Obstet Gynecol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/BF01727477","article-title":"Bromocriptine in pregnancy: safety aspects","volume":"65","author":"P Krupp","year":"1987","journal-title":"Klin Wochenschr"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/09513590.2016.1254177","article-title":"Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy","volume":"33","author":"A Rastogi","year":"2017","journal-title":"Gynecol Endocrinol"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1468-4608.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T20:06:00Z","timestamp":1698955560000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1468-4608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":30,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2021,6,21]]},"published-print":{"date-parts":[[2021,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1468-4608","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]}}}